

# Antidiabetic and Cytotoxic effects of *Cystoseira trinodis* and *Microcystis aeruginosa* extracts

Mohamed A. I. Deyab\*, Ahmed K. A. El- Sayed\*, Ayman Hyder\*, Mamdouh Abdel-Mogib\* and Seham E. A. Abu Ahmed\*+

\*Botany Department, Faculty of Science, Damietta University, New Damietta, Egypt.  
+ corresponding author: E mail: snowwhite201443@yahoo.com

**Abstract:** The present study aimed to determine the hypoglycemic, cytotoxic effects and phytochemical constituents of *Cystoseira trinodis* and *Microcystis aeruginosa* extracts. The GC-MS and <sup>1</sup>H NMR analysis of *C. trinodis* and *M. aeruginosa* extracts revealed the presence of fatty acids, steroids, terpenoids and vitamins which may play an antidiabetic role. The cytotoxic effects of those extracts were tested on the tumor cell lines (HepG2) and the hypoglycemic effects were investigated in alloxan-induced hyperglycemic mice. Fasting blood glucose level showed significant decreased on days 1, 3, 10, 17, 24 and 31 groups treated with *C. trinodis* extract, compared to diabetic groups. The cytotoxic effect of *C. trinodis* petroleum ether extract displayed LD<sub>50</sub> value of 112 mg/ml, while chloroform extract displayed LD<sub>50</sub> value of 77 mg/ml. The two fractions of *Microcystis aeruginosa* had no cytotoxic effect on HepG2 cells.

**Keywords:** Antidiabetic, Cyanophyta, *Cystoseira trinodis*, Cytotoxicity, *Microcystis aeruginosa*, Natural products, Phaeophyta, Phytochemical constituents.

## Introduction

The growth of human population leads to intensification of agriculture and promotes, through eutrophication, development of cyanobacteria. Cyanobacteria contribute significantly to primary productivity of some compounds that have potential biotechnological application and drug production (Muruga *et al.*, 2014). Increased outbreaks of toxic cyanobacteria blooms events resulting from elevated water temperatures and extreme hydrologic events attributable to climate change and increased nutrient loadings associated with intensive agricultural practices (Lunetta *et al.*, 2015). One of the most widespread and bloom-forming species in freshwater is toxic *Microcystis aeruginosa* (Rzymiski *et al.*, 2014). Marine algae are one of the largest producers of biomass in the marine environments (Bhadury and Wright, 2004). Various bioactive compounds are discovered, isolated and used from different classes of algae to develop novel pharmaceuticals (Parsaeimehr and Feng Chen, 2013). Algae contain useful substances including pigments ( $\beta$  carotene, astaxanthin, zeaxanthin, lutein, canthaxanthin, chlorophyll, phycoerythrin, fucoxanthin and phycocyanin), polyunsaturated fatty acids (docosahexaenoic acid, eicosapentanoic acid and arachidonic acid), antioxidants (catalases, polyphenols, superoxide, dismutase and tocopherols), essential amino acids (leucine, aspartic acid, glutamic acid, phenylalanine, asparagine and glycine) and

antimicrobials (tropodithetic acid, labdane diterpenes, brominated hydroquinones and phlorotannins) (Elena *et al.*, 2012). Phenolic-rich extracts from edible marine macro-algae had a potential antidiabetic effect (Nwosu *et al.*, 2011). Brown algae were found to have secondary metabolites most of which are phenolic compound which had medicinal potentials (Abou-Elela *et al.*, 2009) and fucoxanthin which exhibited antidiabetic activities (Maeda *et al.*, 2007). Some species of *Cystoseira* had been studied for its hypoglycemic efficacy (Guiry *et al.*, 2009). Diabetes mellitus is a group of metabolic diseases characterized by elevated blood glucose levels (hyperglycemia) resulting from defects in insulin secretion, insulin action or both (Loghmani, 2005). People with diabetes may develop serious complications such as heart disease, stroke, kidney failure, blindness and premature death (National Diabetes Statistics Report, 2014). Diabetes can be classified into type 1, type 2, gestational diabetes mellitus and specific types of diabetes due to other causes (Diabetes Care, 2015). It is considered a major health problem all over the world. Globally, the number of people who has been diagnosed with diabetes has exploded in the past two decades with 6% per annum increase and by 2025, about 324 million people will be diabetic (Mohammed *et al.*, 2007). Diabetes is associated with increased risk of cancers of the liver, pancreas, endometrium, colon, breast and bladder (Suh and Kim, 2011). As a result, there is a need to search for effective, safe and better antidiabetic agents.

The aim of this study is to screen the phytochemical components, cytotoxicity and antidiabetic effect of the brown alga *Cystoseira trinodis* and the blue-green alga *Microcystis aeruginosa* extracts.

## Materials and Methods

Algal bloom of *Microcystis aeruginosa* with thick gelatinous massive growth layer (3-5 cm) was collected during autumn from El-Manzala Lake with plankton net of 10  $\mu$ m mesh size. *Cystoseira trinodis* had been collected manually from the intertidal zone of Hurghada, Red Sea coast of Egypt. The algae were rinsed several time with saline water and finally with distilled water to remove epiphytes and sediments. The algal samples of both strains were then allowed to dry in air using string net. The dry samples were ground and the dry weight was evaluated and then stored in stoppered bottles in refrigerator (Perumal *et al.* 2012).

Thin layer chromatography (TLC) was performed using pre-coated TLC plates (20 $\times$ 20cm $\times$ 0.2mm) (Silica gel 60GF254). The material to be extracted was generally applied in appropriate solution of 0.1% concentration by means of micropipette at starting point 1.5

cm apart from the lower edge of the plates. The plates were put in a previously cleaned and dried jar containing the suitable eluent. The plates were removed from the jars, allowed to dry spontaneously. The spots were viewed under 254 and 365 nm UV lamps.

The columns employed for this study were made of glass of different dimensions (100cm height and 5 cm radius) ending with tap to regulate the flow rates of liquids. A pad of cotton was inserted into the bottom of the tube to pack the column, the column was held vertically, the tap was closed and then filled with appropriate solvents, allowing it to draw through the pad to expel air bubbles. The column was filled with the silica gel 60, 70-230 mesh (E. Merck) and compacted then the extract was applied as a silica gel supported thin layer, another pad of cotton was inserted into the top of the column. The stationary phase (silica gel) was always covered with sufficient quantity of solvent and never allowed to dry. Then the column was eluted with different solvents of increasing polarities to isolate the fractions.

It performed with an Agilent 6890 gas chromatograph (GC) equipped with an Agilent mass spectrometric (MS) detector, with a direct capillary interface and fused silica capillary column PAS 5ms (30m × 0.32mm × 0.25µm film thickness). Samples were injected under the following conditions: Helium was used as carrier gas at approximately 1 ml/min., pulsed splitless mode. The solvent delay was 3min. and the injection size was 1.0µl. The mass spectrophotometric detector was operated in electron impact ionization mode with ionizing energy of 70e.v. scanning from m/z 50 to 500. The ion source temperature was 230°C and the quadruple temperature was 150°C. The electron multiplier voltage (EM voltage) was maintained 1250 v above auto tune. The instrument was manually tuned using perfluorotributy l amine (PFTBA). The GC temperature program was started at 60°C then elevated to 280°C at rate of 8°C/min. and 10 min. hold at 280°C the detector and injector temperature were set at 280 and 250°C, respectively. Wiley and Nist 05 mass spectral data base was used in the identification of the separated peaks (**Gomathi et al., 2013**).

<sup>1</sup> **H NMR** (H-Proton Nuclear Magnetic Resonance) spectra were recorded on 300 MHz (**BRUKER**). Chemical shifts are given in δ (ppm) relative to TMS as internal standard material at faculty of Science, Kafr El-Sheikh University.

The albino mice *Mus musculus* used in this study had the weights between 20-30 grams and free of physical deformities. The mice were housed in cages (48× 35× 22 cm) with three mice per cage under 12hours light/ 12hours dark cycle (**Caral, 2006**). It was supplied with standard pellet diet and tap water ad libitum throughout the experimental period. They were acclimated

for two weeks in the environment before the actual experiments (**Jalal, 2007**). All mice were randomly divided into six groups with six mice each, three males and three females. Group A was the non-diabetic control group and was untreated with alloxan. Group B was the negative control which was administrated with distilled water. Group C was the positive (+) control group which was treated with glibenclamide (5mg/kg body weight). Group D and E for *C. trinodis* petroleum ether (0.5g/kg B.W.) and chloroform (0.5g/kg B.W.) extracts respectively. Group F and G for *M. aeruginosa* petroleum ether (0.5g/kg B.W.) and chloroform extracts (0.5g/kg B.W.), respectively.

### **Processing of algal material**

After collection, *Microcystis aeruginosa* (200g) and *Cystoseira trinodis* (1Kg) dried samples were overnight soaked in methanol at room temperature then filtered off. The marc was washed several times by methanol then the filtrate was evaporated by rotary evaporator to afford the crude extract (174.91g and 85.03g, respectively).

The algal extracts were packed in a continuous extraction apparatus. Successive extraction to exhaustion was done with solvents of increasing polarity in the following order: petroleum ether (60°C - 80°C) then chloroform. The marc after each extraction was dried until freed from the solvent, before extraction with the next solvent. The obtained two solvent fractions were separately concentrated under reduced pressure, dried to constant weight in vacuum desiccators, weighted and reserved in the refrigerator until further investigation. The petroleum ether extract of *C. trinodis* (6.32g) and *M. aeruginosa* (1.3g) were analyzed by GC/MS.

The chloroform extract of *C. trinodis* (6.5g) and *M. aeruginosa* (9.5g) was loaded on a silica gel-packed column (2Kg) and gradient eluted with a mixture of petroleum ether in ethyl acetate. The effluent was collected in 100 ml fractions. Fractions of *C. trinodis* (12-14), (15-17), (18-24), (26-28), (30-35) and (36-50) and *M. aeruginosa* (12-17), (22-32) and (5-7) were concentrated under reduced pressure at 40°C to a smaller volume (5ml) and monitored by silica gel GF<sub>254</sub> TLC using the suitable solvent system and conc. H<sub>2</sub>SO<sub>4</sub> and methanol (1:1) as a spray reagent. Similar fractions were pooled, concentrated to a small volume (5ml) and left in refrigerator and identified by <sup>1</sup>H NMR.

### **Study of hyperglycemic activity of *C. trinodis* and *M. aeruginosa***

#### **Administration of alloxan to induce diabetes**

A freshly prepared solutions of alloxan (0.15g/kg B.W.) was used to induce diabetes (Wolfson and Wendy, 2007; Tanquilut *et al.*, 2009; Kumar *et al.*, 2009 and Rupasinghe *et al.*, 2003). The administration of alloxan and treatments were done via intraperitoneal injection using 0.5 ml insulin syringe with 30 gauge needles on the lower right or left quadrant and lateral to the umbilicus. This was done by a standard one-hand restraint technique according to Fjellberg (2006).

### **Processing of experimental animals**

Mice were left 2 weeks for acclimatization. The experiment ran for 31 days excluding the two weeks acclimatization period of the mice. On Day zero, mice were fasted for 12 hours. On Day 1, body weight, body temperature and blood samples were collected. Fasting blood glucose level was determined using the glucometer System - GlucoDr™ Plus. After the fasting blood glucose level was determined, alloxan was administered per intraperitoneal injection for the treatment groups B--to--G to induce hyperglycemia. Group A (six mice) was left untreated. After 48 hours, body temperature, weight and fasting blood glucose level were recorded. Those mice with >200mg/dl were considered diabetic according to Li *et al.* (2009). Those diabetic mice were randomly distributed to the different treatment groups (six mice per group) at a dose of 0.5 g/Kg. After 6 hours, Glibenclamide was administered to mice of Group C as positive control group. After the administration of different treatments, the blood glucose level was determined thrice initially after 1 hour with an interval of one hour each. The administration of respective treatments was continuous until day 30. Fasting blood glucose level and body temperature and weight were measured in days 10, 17, 24 and 31.

### **Oral glucose tolerance test (oGTT)**

After 12-hr fasting, a blood sample was collected to measure the fasting blood glucose value. Mice were then provided per oral gavage with glucose solution (2g/Kg body weight). Blood glucose was measured every 30 min for 2 hours (Buse *et al.*, 2011).

### **Cytotoxicity assay of *C. trinodis* and *M. aeruginosa* extracts using HepG2 cell line**

Cytotoxic activity was measured by apoptotic cell death scored by cell surface evaluation and nuclear morphology. The neutral red method, as originally developed by Borenfreund and Puerner (1985) was applied. The cultures were removed from incubator into laminar flow hood and 0.33% neutral Red Solution was added in an amount equal to 10% of the culture medium volume. Cultures were returned to incubator for 2 hours. At the end of the incubation period, the medium was carefully removed and the cells quickly rinsed with PBS. The fixative

or wash solution removed and the incorporated dye are then solubilized in a volume of Neutral Red Assay Solubilization Solution equal to the original volume of culture medium. The cultures were allowed to stand for 10 minutes at room temperature. The absorbance was measured spectrophotometrically at a wavelength of 540 nm. The background absorbance of multiwell plates was also measured at 690 nm and subtract from 540 nm measurement.

### Statistical analysis

Results were expressed as means  $\pm$  SEM. For the comparison among groups, data were analyzed with one-way Analysis of Variance (ANOVA) followed by the Tukey-Kramer post-hoc multiple comparison test. The significant level was set at  $p < 0.05$  using SPSS version 18.

### Results

The petroleum ether extract of *Microcystis aeruginosa* contained 19 compounds which were identified of which 18 compounds were aliphatic and only one was aromatic. The aliphatic compounds were 10 fatty acids, 4 alkanes, fatty alcohol and 2 monoterpenoids. Hexadecanoic acid (palmitic acid) was found as major constituent with the peak area 48.43 % and retention time 21.71. In aromatic group, the compound 7-methoxy 2, 2-dimethyl-2H-1-benzoate with the peak area 0.13 % and retention time 15.41 (Table 1). In the chloroform extract of *C. trinodis* and *M. aeruginosa* fractions were analyzed by  $^1\text{H}$  NMR then GC/MS which indicated the presence of mixtures of fatty acids (Table 2, 3, 4 and 5).

*Cystoseira trinodis* petroleum ether extract was analyzed by GC/MS. About 50% of the peaks (20 compounds) were identified according to Nist library to afford compounds from (1) to (20). Totally 20 compounds were identified, of which 17 compounds

were belonged to aliphatic group and 3 compounds were aromatic. The aliphatic group comprised 3 alkanes, 11 fatty acids, 2 diterpenes, one steroid and one carotenoid. Hexadecenoic acid methyl ester was found as major constituents with the peak area 6.82 % and retention time 25.06 followed by 4, 8, 12, 16-tetramethylheptadecane with the peak area 3.69 % and retention time 22.25. The aromatic group possessed benzaldehyde with 0.47 % and retention time 3.60.

**Table 1. Identified compounds of *Cystoseira trinodis* and *Microcystis aeruginosa* petroleum ether fractions**

<i>Cystoseira trinodis</i>			<i>Microcystis aeruginosa</i>		
Compound name	Rt	Area %	Compound name	Rt	Area %
Hexadecane	7.82	0.36	n-heptadecane	16.94	3.25
Heptadecane	19.24	0.42	Octadecane	18.25	2.82
Eicosane	20.71	0.14	Nonadecane	19.49	0.53
Dodecanoic acid	17.51	0.18	Dodecanoic acid	15.09	0.13
Tetradecanoic acid	20.40	2.94	Hexadecanoic acid	21.71	48.43
n-hexadecanoic acid	22.47	2.08	Heptadecanoic acid	22.11	1.04
Octadecanoic acid	25.24	1.83	Octadecanoic acid	23.08	2.26
Tetradecanoic acid methyl ester	19.61	0.45	Nonanoic acid, methyl ester	12.94	0.06
Hexadecanoic acid methyl ester	21.98	0.75	tetradecanoic acid methyl ester	17.20	0.40
12-methyltetradecanoic acid	19.91	0.51	hexadecanoic acid methyl ester	20.08	13.9
6,10,14-trimethyl pentadecanone	21.22	0.34	2-methyl-heptadecane	17.68	0.25
Neophytadiene	27.13	0.28	Iso-octadecanoic acid	22.82	1.02
4,8,12,16-tetra methyl heptadecane	22.25	3.69	Hexanedioic acid mono methyl ester	11.22	0.04
Hexadecenoic acid methyl ester	25.06	6.82	Nonanoic acid	10.46	0.08
9-octadecenoic acid methyl ester	24.35	1.44	6,10,14-trimethyl-2-pentadecanone	18.87	1.60
9-octadecenoic acid	26.12	0.22	Iso-octadecanoic acid	11.81	0.08
5,8,11,14-tetra eicosatetraenoic acid	21.11	0.21	Oleyl alcohol	13.55	0.14
Benzaldehyde	3.60	0.47	3-oxo- $\beta$ -ionone	16.66	0.25
Fucosterol	35.97	0.15	2,2-dimethyl-7-methoxy-2,3-dihydro-2H-benzo[b]thiene	15.41	0.13
Vitamin E	40.09	1.73			



**Table 2. Identified compounds from *Cystoseira trinodis* fractions (1-3)**

Compound name	R <sub>t</sub>	Area %
Pleiocarpamine	5.14	0.88
2-Pentadecanoic acid 2-glyceride	35.89	1.81
3-Palmitic acid 2-tetradecyloxyethyl ester	36.77	3.55
4-Octadecanoic acid 1-glyceride (1-Monostearin)	37.95	1.77
1,2-dipalmitin	39.83	1.16
Isochiapin B	40.84	6.47
Oleic acid	41.40	2.17
1-Monopalmitin	45.33	5.98
Ethyl-isoalcholate	61.44	6.85

**Table 3. Identified compounds from *Microcystis aeruginosa* fraction (12-17)**

Compound name	R <sub>t</sub>	Area %
2-pentadecanone, 6,10,14-tri-methyl	37.77	1.46
Tetradecanoic acid, 3-hydroxy-methyl ester	38.64	0.94
Palmitic acid, methyl ester	39.80	5.54
Palmitic acid	41.90	47.03
Oleic acid	44.07	4.85

**Table 4. Identified compounds from *Microcystis aeruginosa* fraction (22-32)**

Compound name	R <sub>t</sub>	Area %
Butene-2-one, 4-(4-hydroxy-2,2,6-trimethyl-7-oxabicyclo [4,1,0] hept-1-yl)	34.06	0.74
Loliolide	36.57	0.24
2-pentadecanone, 6,10,14-trimethyl	37.77	0.45
Heptadecenoic acid	39.07	0.35
Palmitic acid, methyl ester	39.80	2.07
Palmitic acid	40.76	7.58
Octadecanoic acid	45.97	0.31
9-octadecenamide	46.10	1.34

**Table 5. Identified compounds from *Microcystis aeruginosa* fraction (5-7)**


Compound name	R <sub>t</sub>	Area %
1-bicyclo [3-1,1]heptane, 6,6-dimethyl-2-methylene	10.40	0.97
Tetradecanoic acid, methyl ester	34.81	0.35
Tetradecanoic acid, 12-methyl-, methyl ester	36.40	0.54
Octadecan	36.60	0.28
2-pentadecanone 6,10,14-trimethyl	37.80	5.08
Heptadecenoic acid	39.09	0.24
Palmitic acid, methyl ester	39.81	78.54
Palmitic acid, ethyl ester	41.48	0.71
Heptadecanoic acid, methyl ester	42.25	0.44
Octadecanoic acid, methyl ester	44.49	2.59

**Effect of algal fractionized extracts on fasting blood glucose levels**



### Short – term effect on blood glucose:

Alloxan increased significantly blood glucose in all alloxan-treated groups. On the 3<sup>rd</sup> day, the acute effect of the algal extract on blood glucose was tested. Group C was treated with the anti-diabetic drug Glibenclamide, while groups D-to-G were exposed to different extracts. Figure (1) shows that fasting blood glucose decreased gradually over 3h in groups A (non-diabetic control group), C (+ve control), D and E (treated groups by *C. trinodis* extracts). Blood glucose of groups B (-ve control) and G (treated group with chloroform extract of *M. aeruginosa*) remained elevated. One hour after the administration of respective treatments for Groups C (+ve control), F and G (treated group with chloroform extract of *M. aeruginosa*) showed a significantly ( $p < 0.0001$ ) lower fasting blood glucose than Group B (diabetic control group). One hour later, a significant drop of blood glucose level was observed (20% in Group C, 52% in Group D and 61% in Group E. the results were similar after 2 and 3 hours.



**Figure 1. Fasting blood glucose (mg/dl) after different treatments on day 3 showing acute glucose lowering effect of algal extracts. Data are means  $\pm$  SEM. \*\*  $p < 0.001$  = significant.**

### Long – term effect on blood glucose:

The results showed that on days 1, 3, 10, 17, 24 and 31 the fasting blood glucose of group A, C, D and E were decreased gradually with days. On the other hand, group B still increased at all the experiment days. Group F and G were highly increased until mice death (Table 6). The fasting blood glucose level mean on day 1 showed no intra group significance ( $p = 0.467$ ). ANOVA showed significant difference among groups on days 3, 7, 10, 17, 24 and 31. On day

3, forty-eight hours after the administration of alloxan to the diabetic groups B, C, D, E, F and G which exhibited hyperglycemia and had significant fourfold ( $p < 0.0001$ ) increase in the fasting blood glucose level as compared to Group A (Normal non-diabetic group). On day 10, fasting blood glucose mean of Group A was significantly different compared to Group B ( $p < 0.000$ ), while no significance between groups C and D ( $p < 0.077$ ) compared to Group F and G ( $p < 0.000$ ). On day 17, fasting blood glucose mean of Group C was significantly different compared to Group E ( $p < 0.005$ ), Group F ( $p < 0.000$ ) and Group G ( $p < 0.000$ ) while no significant difference to Group D ( $p < 0.336$ ). On day 24, Group C, fasting blood glucose mean was significantly different compared to all the other groups ( $p < 0.000$ ). It was also observed that the fasting blood glucose mean in normal mice (Group A) ( $p < 0.0001$ ) was constant over the course of the experiment and was significantly different from those of alloxan-induced diabetic mice of Group B (Table 6).

**Table 6. Effects of algal extracts on the fasting blood glucose level of normal and alloxan-diabetic albino mice**

Groups treatment	Fasting blood glucose level (mg/dl)											
	Day 1	P	Day 3	P	Day 10	P	Day 17	P	Day 24	P	Day 31	P
A Normal (Non Diabetic)	98± 17.6		100± 1.2		87± 1.2		85± 2.6		89± 0.6		78± 1.5	
B Diabetic (Alloxan only)	109± 2.1	0.429	317± 1.5	0.000**	265± 3.2	0.000**	285± 2.9	0.000**	285± 2.9	0.000**	296± 2.9	0.000**
C Glibenclamide	115± 7.4	0.673	207± 1.8	0.000**	95± 4.4	0.000**	96± 1.8	0.000**	87± 1.2	0.000**	112± 1.7	0.000**
D ( <i>C. trinodis</i> ) (Pet. Ether)	99± 11.4	0.279	312± 6	0.000**	115± 7.6	0.077	98± 0.3	0.336	132± 4.4	0.000**	121± 4.9	0.016*
E ( <i>C. trinodis</i> ) (Chloroform)	113± 10.7	0.869	460± 5.1	0.000**	122± 6	0.024*	107± 2.6	0.005*	136± 2.3	0.000**	78± 0.6	0.000**
F ( <i>M. aeruginosa</i> ) (Pet. Ether)	126± 7.2	0.429	336± 24.7	0.000**	415± 4.4	0.000**	died		died		died	
G ( <i>M. aeruginosa</i> ) (Chloroform)	106± 3.8	0.544	484± 7.1	0.000**	496± 15.9	0.000**	died		died		died	

Values are mean ± SEM: \*  $p < 0.05$  = significant; \*\*  $p < 0.001$ ; NS= Non significant: Group A and B is compared: Group B and C are compared: Group C is compared with Groups D, E, F and G.

### Body weight

As shown in Table (7), on day 1, all groups had no significant difference in body weight ( $p < 0.789$ ). Groups B, C and G exhibited loss of body weight with significant ( $p < 0.05$ ) compared to Group A on day 3, while, the other groups (D and E) exhibited a gradient increase of body weight. On day 10, Groups D and E showed a significant difference ( $p < 0.05$ ) in body weight but all the other groups had no significance. On day 17, groups E, F and G were not significantly different compared to group C. On the other hand, groups D and E had non-

significant difference compared to group C on day 24. On day 31, the results showed that groups B and C had a significant increase on body weight.

### Body temperature

Body temperature was ranged between 35.5 °C to 37.8 °C. On days 1, 3, 17, 24 and 31, the body temperature means had no significant intra-group variation ( $p > 0.05$ ). It gives the highest degree in group B, but group A, C, D and E showed few differences in its temperature degree. For groups D and E, a significant difference ( $p < 0.05$ ) was observed compared to group C on days 3 and 10 while groups F and G were non-significant (Table 8).

**Table 7. Effect of algal extracts on the body weight (g) in normal and alloxan diabetic albino mice**

Groups treatment	Body weight in grams of mice					
	Day 1	Day 3	Day 10	Day 17	Day 24	Day 31
A Normal (Non Diabetic)	23±0.4	24±0.5	24±0.5	23±0.5	23±0.3	24±0.3
B Diabetic (Alloxan only)	25±1 <sup>NS</sup>	19±0.4 <sup>**</sup>	23±1.4 <sup>NS</sup>	22±0.3 <sup>NS</sup>	23±0.3 <sup>NS</sup>	20±0.3 <sup>**</sup>
C Glibenclamide	23±1 <sup>NS</sup>	22±0.6 <sup>**</sup>	21±0.4 <sup>NS</sup>	22±1.4 <sup>NS</sup>	22±0.4 <sup>*</sup>	22±0.1 <sup>*</sup>
D ( <i>C. trinodis</i> ) (Pet. Ether)	26±2.6 <sup>NS</sup>	25±0.3 <sup>*</sup>	19±0.3 <sup>*</sup>	20±0.5 <sup>*</sup>	21±0.3 <sup>NS</sup>	22±0.2 <sup>NS</sup>
E ( <i>C. trinodis</i> ) (Chloroform)	24±2 <sup>NS</sup>	26±0.4 <sup>**</sup>	26±0.5 <sup>**</sup>	21±0.5 <sup>NS</sup>	22±0.5 <sup>NS</sup>	23±1 <sup>NS</sup>
F ( <i>M. aeruginosa</i> ) (Pet. Ether)	24±1 <sup>NS</sup>	22±1 <sup>NS</sup>	21±0.8 <sup>NS</sup>	die	die	die
G ( <i>M. aeruginosa</i> ) (Chloroform)	20±2.4 <sup>NS</sup>	21±0.4 <sup>*</sup>	22±0.6 <sup>NS</sup>	die	die	die

Values are mean ± SEM: \*  $p < 0.05$  = significant; \*\*  $p < 0.001$ ; NS= Non significant: Group A and B is compared: Group B and C are compared: Group C is compared with Groups D, E, F and G.

**Table 8. Effect of algal extracts on the body temperature (°C) in normal and alloxan diabetic albino mice**

Groups treatment	Body Temperature (°C)					
	Day 1	Day 3	Day 10	Day 17	Day 24	Day 31
A Normal (Non Diabetic)	35.7±0.3	36±0.1	36.2±0.1	36.1±0.1	36.5±0.1	36.3±0.1
B Diabetic (Alloxan only)	35.8±0.4 <sup>NS</sup>	36.6±0.1 <sup>*</sup>	36.4±0.1 <sup>NS</sup>	35.9±0.1 <sup>*</sup>	36.7±0.1 <sup>NS</sup>	37.8±0.1 <sup>**</sup>
C Glibenclamide	35.8±0.4 <sup>NS</sup>	36.3±0.1 <sup>NS</sup>	36.1±0.1 <sup>NS</sup>	36.2±0.2 <sup>*</sup>	36.3±0.1 <sup>*</sup>	36.7±0.1 <sup>**</sup>
D ( <i>C. trinodis</i> ) (Pet. Ether)	36.2±0.2 <sup>NS</sup>	36±0.0 <sup>NS</sup>	36.3±0.1 <sup>NS</sup>	36.1±0.1 <sup>NS</sup>	36.4±0.1 <sup>NS</sup>	36.6±0.1 <sup>NS</sup>
E ( <i>C. trinodis</i> ) (Chloroform)	36.2±0.1 <sup>NS</sup>	35.9±0.2 <sup>*</sup>	35.7±0.3 <sup>NS</sup>	35.9±0.1 <sup>*</sup>	36.4±0.2 <sup>NS</sup>	36.7±0.1 <sup>NS</sup>
F ( <i>M. aeruginosa</i> ) (Pet. Ether)	36.4±0.2 <sup>NS</sup>	36.1±0.1 <sup>NS</sup>	35.8±0.4 <sup>NS</sup>	die	die	die
G ( <i>M. aeruginosa</i> ) (Chloroform)	36.4±0.2 <sup>NS</sup>	36.4±0.1 <sup>NS</sup>	35.5±0.3 <sup>NS</sup>	die	die	die

Values are mean ± SEM: \*  $p < 0.05$  = significant; \*\*  $p < 0.001$ ; NS= Non significant: Group A and B is compared: Group B and C are compared: Group C is compared with Groups D, E, F and G.

### Oral glucose tolerance test (oGTT)

Figure (2) showed that, at zero time, the fasting blood glucose were 77, 182, 172, 180 and 171 mg/dl for groups A (non-diabetic control group), B (-ve control), C (+ve control), D and E (treated with *C. trinodis* extracts), respectively. After 30 min., groups A, C, D and E have been recorded the maximum rate of fasting blood glucose then decreased after 2h to reach 80, 171, 179 and 175 mg/dl, respectively. On the other hand, by increasing of time, the fasting blood glucose increased.




Figure 2. Fasting blood glucose (mg/dl) during oGTT of all groups




Figure 3. The Cytotoxic effect of *cystoseira trinodis* and *Microcystis aeruginosa* fractions against HepG2 cells

### Cytotoxicity test

Treatment with various concentrations of *C. trinodis* extract caused a dose-dependent cytotoxicity in HepG2 cells. Maximum viability rate was observed at 3.1 mg/ml concentration while 50 % viability was observed at 112 mg/ml concentration in ether extract. Also, Chloroform extract showed the maximum viability rate at 3.1 mg/ml concentration but 50% viability was observed at 77 mg/ml concentration (Figure 3). On the other hand, the two fractions of *M. aeruginosa* are deadly affect HepG2 cells.

## Discussion

Alloxan itself is nontoxic. It is rapidly taken up by the pancreatic  $\beta$ -cells. Alloxan has a direct effect on islet cell permeability and acts at the site of hexose transport as it inhibits glucose-stimulated insulin release (Tomita *et al.*, 1994). It also interferes with the generation of glucose derived energy by inhibiting glycolytic flux and pyruvate oxidation (Borg *et al.*, 1979). This destruction was attributed with high blood glucose level and was recorded in diabetic mice (Group B) as compared to normal control mice (Group A) (Table 6). Alloxan-induced model of hyperglycemia in mice was used to investigate the effect of two solvent fractions of *C. trinodis* and *M. aeruginosa* on lowering of blood glucose level. Unfortunately, we couldn't complete groups F and G (*M. aeruginosa* extracts) due to death of mice (Table 6). It is well known, however, that *M. aeruginosa* produce the microcystin-LR toxin that may cause a haemorrhagic shock (Hermansky *et al.*, 1990). After intraperitoneal injection of doses of *M. aeruginosa*, microcystin appears to be transported by bile acids transporter in both the intestine and the liver. About 70% of the toxin was rapidly localized in the liver (Runnegar *et al.*, 1991) via a carrier-mediated transport system followed by the inhibition of serine protein phosphatases 1 and 2A. The protein phosphorylation imbalance causes disruption of the liver cytoskeleton which leads to massive hepatic haemorrhage that can cause death (Romanowska *et al.*, 2002). Thus, the two fractions of *Microcystis aeruginosa* had no cytotoxic effect on HepG2 cells (Figure 3). Moreover, all extracts of *M. aeruginosa* reveals the presence of palmitic acid which were associated with higher diabetes risk (Wenjie *et al.*, 2015) with the highest percentage (Table 1, 3, 4 and 5). *C. trinodis* fractions were effective in lowering the blood glucose level in alloxan-induced diabetic mice (Table 6, Figures 1 and 2) and had a cytotoxic effect against HepG 2 (Figure 3). These effects may be attributed to the presence of secondary metabolites which identified by the GC-MS analysis on various extracts of *C. trinodis* and enumerated along with molecular formula, retention time, molecular weight and peak area. GC-MS analysis of petroleum ether extract of *C. trinodis* revealed the presence of hydrocarbons, unsaturated fatty acids, steroid, terpenoids

and vitamin E (Table 1). While, the chloroform extract reveals the presence unsaturated fatty acids (Table 2). Fucosterol is the primary sterol found in brown algae like *C. trinodis*. Recently, considerable interest has been generated regarding fucosterol due to its potential antioxidant; anti-inflammatory, antidiabetic effects that made it as an effective hepatoprotective agent that could be useful for preventive therapies against oxidative stress-related hepatotoxicity (Choi *et al.*, 2015). Poly unsaturated fatty acids reduce insulin resistance and thus, decrease the risk of type 2 diabetes (Das, 2002). This is accordance with Das and Suresh (2001) who suggest that polyunsaturated fatty acids can prevent alloxan-induced diabetes mellitus in experimental animals and may be useful to prevent diabetes mellitus in the high-risk population. The compounds identified by GC-MS in all extracts are medicinally valuable and possess various pharmaceutical applications even in minimal dose. For instance, hexadecanoic acid which is a palmitic acid compound found to be anti-oxidant, anti-hypocholesterolemic, nematocidal, pesticide, turbicant activities and hemolytic 5-alpha is a reductase inhibitors. These results are strengthened by the findings of Sermakkani and Thangapandian (2012) who observed the presence of this compound in methanol extract of *Cassia italica* leaves. Unfortunately, palmitic acid lowers insulin resistance and incident diabetes (Mozaffarian *et al.*, 2010). On the other hand, the percentage of arachidonic acid (5, 8, 11, 14-tetraicosatetraenoic acid) shown to positively correlated with insulin sensitivity (Das, 2002). Oleic acid (9-octadecenoic acid) reported to have an anti-inflammatory, nematocidal, insectifuge, anticancer and antidiabetic properties. The monounsaturated oleic acid did not affect DNA fragmentation and induced  $\beta$ -cell proliferation. Moreover it prevented the deleterious effects of both palmitic acid and high glucose concentration (Maedler *et al.*, 2003). The combinations of essential fatty acids and vitamin E have general utility in the treatment of a variety of diseases such as disorders of inflammation, in alcoholism and in schizophrenia complications (Horrobin, 1992). Di-terpenoid compounds (4, 8, 12, 16-tetramethylheptadecane and neophytadiene) were reported to possess antimicrobial, anticancer and anti-inflammatory activity (Praveen *et al.*, 2010) and exhibited a significant decrease in blood glucose level (Lu *et al.*, 2010). The steroid component of the petroleum ether fraction of *C. trinodis* could support the fasting blood glucose level lowering mechanism and assist indirectly the health of the diabetic mice since these metabolites had been reported in ethanolic extract of *Musa* fruits to have lipid lowering effect (Kaimal *et al.*, 2009).

## Conclusion

In the present study, 20 and 19 chemical compounds have been identified by GC-MS analysis from the petroleum ether, while 10 and 19 chemical compounds have been identified from the chloroform extract of *C. trinodis* and *M. aeruginosa*, respectively. *M. aeruginosa* had no antidiabetic and deadly cytotoxic effect on HepG2 cells. On the other hand, *C. trinodis* showed hypoglycemic and antitoxic properties. *Microcystis aeruginosa* was found to contain high percentage of palmitic acid. Meanwhile, *Cystoseira trinodis* contains terpenoides, steroids, unsaturated fatty acids (arachidonic and oleic acid) and vitamin E. These compounds may mediate the beneficial effect of our extracts. Further studies should be performed including isolation and purification of the bioactive chemical compounds present in the extract in order to prove their potential in clinical studies.

## References

- ABOUELELA, M. GEHAN, A. HANAN, A. H. HASSAN, M. A. IBRAHIM, AND OKBAH. 2009.** Marine natural products and their potential applications as anti-infective agents. *Journal of World Applied Society* 7(7): 872-880.
- BHADURY, P., AND P. C. WRIGHT. 2004.** Exploitation of marine algae: biogenic compounds for potential antifouling applications. *Planta* 219: 561-578.
- BORENFREUND, E., AND J. A. PUERNER. 1985.** Toxicity determined in vitro by morphological alterations and neutral red absorption. *Toxicology Letters* 24: 119-124.
- BORG L, S. J. EIDE, A. ANDERSON, AND C. HELLERSTROM. 1979.** Effects in vitro of alloxan on the glucose metabolism of mouse pancreatic cells. *Journal of Biochemistry* 182: 797-802.
- BUSE J. B., K. S. POLONSKY, C. F. BURANT, S. MELMED, K. S. POLONSKY, P. R. LARSEN, H. M. KRONENBERG, AND P. R. LARSEN. 2011.** Type 2 diabetes mellitus. In: eds. *Williams Textbook of Endocrinology*. 12th ed. Philadelphia, Pa.: Elsevier Saunders; chapter 31. *Cells. Stain Technology* 48: 135-136.
- CARAL, B. J. 2006.** Hypoglycemic effect of the virgin oil of coconut on the blood glucose level of alloxan-induced hyperglycemic albino mice (*Mus musculus*). Unpublished Master's Thesis, The University of San Carlos Cebu City, Philippines pp. 21.
- CHOI, J. S., Y. R. HAN, J. S. BYEON, S. Y. CHOUNG, H. S. SOHN, AND H. A. Jung. 2015.** Protective effect of fucosterol isolated from the edible brown algae, *Ecklonia*



- stolonifera and *Eisenia bicyclis*, on tert-butyl hydroperoxide- and tacrine-induced HepG2 cell injury. *Journal of Pharm Pharmacology* 10: pp. 1111.
- DAS, U. N. 2002.** Long-chain polyunsaturated fatty acids and diabetes mellitus. *The American Journal of Clinical Nutrition* 75(4):780-781.
- DAS, U. N., AND Y. SURESH. 2001.** Protective action of arachidonic acid against alloxan-induced cytotoxicity and diabetes mellitus. *Prostaglandins, Leukotrienes and Essential Fatty Acids* 64(1): 37-52.
- DIABETES CARE. 2015. Standards of medical care in diabetes.** *The journal of clinical and applied research and Education* 38(1): 58-59.
- ELENA, I., M. HERRERO, J. A. MENDIOLA, AND M. CASTRO-PUYANA. 2012.** Extraction and Characterization of Bioactive Compounds with Health Benefits from Marine Resource: Macro and Micro Algae, Cyanobacteria and Invertebrates. *Marine Bioactive Compounds* 55-98.
- FJELLBERG, G. 2006.** The Norwegian reference center for laboratory animal science and alternatives: Saphenous vein puncture for blood sampling of the mouse. <http://film.oslovet.veths.no/saphena/index.html>.
- GOMATHI, D., M. KALAISELVI, G. RAVIKUMAR, K. DEVAKI, AND C. UMA. 2013.** GC-MS analysis of bioactive compounds from the whole plant ethanolic extract of *Evolvulus alsinoides* (L.) L. *Journal of Food Science. Technology* 10 (1007)/s13197-013-1105-9.
- GUIRY, M. D., J. AGARDH, M. J. COSTELLO, P. BOUCHET, G. BOXSHALL, C. ARVANTIDIS, AND W. APPELTANS. 2009.** *Cystoseira montagnei*. European Register of Marine Species at <<http://www.marbef.org/data/aphia.php?p=taxdetails&id=145525>.
- Hermansky, S. J., P. J. Casy, AND S. J. Stohs 1990.** Cuclosporin A – a chemoprotectant against microcystin-LR toxicity. *Toxicology Letters* 54: 279-285.
- Horrobin DF. 1992.** Treating tardive dyskinesia with essential fatty acid compositions. United States Patent 5,120,760.
- <http://www.elesvier.com/locate/foodchem>.

- JALAL, R., S. M. BAGHIERI, A. MOGHIMI, AND M. B. RASULI. 2007.** Hypoglycemic effect of aqueous shallot and garlic extracts in rats with fructose-induced insulin resistance. *Journal of Clinical Biochemistry Nutrition* 41: 218-223.
- KAIMAL S., K. S. SUJANTHA, AND S. GEORGE. 2009.** Hypolipidemic and antioxidant effects of fruits of *Musa pAAA*(Chenkadali) in Alloxan induced diabetic rats. *Indian Journal of Experimental Biology* 48: 165-173.
- KUMAR, A., R. HAVARASAN, T. JAYACHANDRAN, AND M. DECARAMA. 2009.** Phytochemicals investigation on a tropical plant. *Syzygium cumini* from Kattuppalayam. Erode District, Tamil Nadu. South India. *Pakistan Journal of Nutrition* 8(1): 83-85.
- LI, F., GAO, AND PENG FENG. 2009.** Preparation and antidiabetic activity of polysaccharide from *Portulaca oleracea* L. *African Journal of Biotechnology* 8 (4): 569-573.
- LOGHMANI, E. 2005.** Diabetes mellitus: Type 1 and Type 2. Guidelines for Adolescent Nutrition Services, pp 167. [http://www.epi.umn.edu/let/pubs/adol\\_book.shtm](http://www.epi.umn.edu/let/pubs/adol_book.shtm).
- LU, X., H. CHEN, P. DONG, L. FU, AND X. ZHANG. 2010.** Phytochemical characteristics and hypoglycaemic activity of fraction from mushroom *Inonotus obliquus*. *Journal Science of Food Agriculture* 90(2): 276-280.
- LUNETTA, R. S., B. A. SCHAEFFER, R. P. STUMPF, D. KEITH, S. A. JACOBS, AND M. S. Murphy. 2015.** Evaluation of cyanobacteria cell count detection derived from MERIS imagery across the eastern USA. *Remote sensing of Environment* 157:24-34.
- MAEDA, H., M. HOSOKAWA, T. SASHIMA, AND K. MIYASHITA. 2007.** Dietary combination of fucoxanthin and fish oil attenuates the weight gain of white adipose tissue and decrease blood glucose in obese/diabetic KK-Ay mice. *Journal of Agricultural Food Chemistry* 55:7701-7706.
- MAEDLER, K., J. OBERHOLZER, P. BUCHER, G. A. SPINAS, AND M. Y. DONATH. 2003.** Monounsaturated Fatty Acids Prevent the Deleterious Effects of Palmitate and High Glucose on Human Pancreatic  $\beta$ -cell Turnover and Function. *Diabetes* 52:726-733.
- MOHAMMED, A., A. B. ADELAIYE, M. S. ABUBAKAR, AND E. M. ABDURAHMAN. 2007.** Effects of aqueous extract of *Ganoderma lucidum* blood

glucose levels of normoglycemic and alloxan-induced diabetic Wister rats. *Journal of Medicinal Plants Research* 1(2): 34-37. *Letters* 24:119-124.

**MOZAFFARIAN, D., H. CAO, I. B. KING, R. N. LEMATTRE, X. SONG, D. S. SISCOVICK, AND S. HOTAMISLIGHT. 2010.** Trans-Palmitoleic Acid, Metabolic Risk Factors and New-Onset Diabetes in U.S. Adults. *Annals of Internal Medicine* 153: 790-799.

**MURUGA, B. N., J. M. WAGACHA, J. M. KABARU, N. AMUGUNE, AND S. M. DUBOISE. 2014.** Effect of physicochemical conditions on growth rates of cyanobacteria species isolated from Lake Magadi, a soda lake in Kenya. *WebPub Journal of Scientific Research* 2(5): 53-62.

**NATIONAL DIABETES STATISTICS REPORT. 2014.** Estimates of Diabetes and Its Burden in United States, <http://www.cdc.gov/diabetes>.

**NWOSU, F., J. MORRIS, V. A. LUND, D. STEWART, H. A. ROSS, AND G. J. MCDOUGALL. 2011.** Anti-proliferative and potential anti-diabetic effects of phenolic-rich extracts from edible marine algae. *Food chemistry* 126:1006-1012.

**PARSAEIMEHR, A., AND Y. FENG CHEN. 2013.** Algal bioactive diversities against pathogenic microbes. *Microbial pathogens and strategies for combating them: science, technology and education* 796-803.

**PERUMAL, P. C., D. SOPHIA, C. A. RAJ, P. RAGAVENDRAN, T. STARLIN, AND V. K. GOPALAKRISHNAN. 2012.** In vitro antioxidant activities and HPTLC analysis of ethanolic extract of *Cayratia trifolia* (L.). *Asian Pac. J. Trop. Dis.*, 2: S952-S956.

**PRAVEEN, K. P., S. KUMARAVEL, AND C. LALITHA. 2010.** Screening of antioxidant activity, total phenolics and GC-MS study of *Vitex negundo*. *African Journal Biochemistry Research* 4(7): 191-195.

**ROMANOWSKA-DUDA, Z., J. MANKIEWICZ, M. TARCZYNSKA, Z. WALLER, AND M. ZALEWSKI. 2002.** The effect of toxic cyanobacteria (blue green algae) on water plants and animal cells. *Polish Journal of Environmental Studies* 11: 561-566.

**RUNNEGAR, M. T. C., R. G. GERDES, AND I. R. FALCONER. 1991.** The uptake of the cyanobacterial hepatotoxin microcystin by isolated rat hepatocytes. *Toxicon*, 29: 43-51.

**RUPASINGHE, H. P., C. J. JACKSON, V. POYSA, C. DI BERADO, J. D. BEWLEY, AND J. JENKINSON. 2003.** Soyasapogenol A and B distribution in Soybean

(Glycine Max L.Merr) in relation to seed physiology, genetic variability and growing location. *Journal of Agricultural Food Chemistry* 51: pp. 5888.

**RZYMSKI, P., B. PONIEDZIALEK, P. NIEDZIELSKI, P. TABACEZEWSKI, AND K. WIKTOROWICZ. 2014.** Cadmium and Lead toxicity and bioaccumulation in *Microcystis aeruginosa*. *Front. Environmental Science Engineering* 8(3): 427-432.

**SERMAKKANI, M., V. THANGAPANDIAN. 2012.** GC-MS analysis of *Cassia italic* leaf methanol extract. *Asian Journal of Clinical Pharmacy Research* 5(2): 90-94.

**SUH, S., K. W., KIM. 2011.** Diabetes and cancer: is diabetes causally related to cancer? *Journal of Diabetes Metabolites* 35:193-198.

**TANQUILUT, N., M. R. C. TANQUILUT, M. A. C. ESTACIO, E. B. TORRES, J. C. ROSARIO, AND B. A. S. REYES. 2009.** Hypoglycemic effect of *Lagerstroemia speciosa* (L.) Pers. on alloxan-induced diabetic mice. *Journal of Medicinal Plants Research* 3(12): 1066-1071.

**TOMITA, T., P. E. LACY, F. M. NATSCHINSKY, AND M. L. MCDANIEL. 1994.** Effect of alloxan on insulin secretion in isolated rat itself perfused in vitro. *Diabetes* 23: 517-524.

**WENJIE, M. A., H. Y. W. JASON, Q. WANG, R. N. LEMAITRE, K. J. MUKAMAL, L. DJOUSSÉ, I. B. KING, S. XIAOLING, M. L. BIGGS, J. A. DELANEY, J. R. KIZER, D. S. SISCOVIC, AND D. MOZAFFARIAN. 2015.** Prospective association of fatty acids in the de novo lipogenesis pathway with risk of type 2 diabetes: the Cardiovascular Health Study. *American Journal Clinical Nutrition* 101: 153-163.

**WOLFSON and WENDY. 2007.** Leapin' Lizards: Amylin targets diabetes and obesity via incretins. DOI 10.1016/j.chembiol.2007.03.005. 236. *Chemistry & Biology* 14: 43-23.